Analyzing the health and economic effects of reducing nicotine in cigarettes for at-risk groups
Health and economic impact analysis of a reduced nicotine cigarette policy on vulnerable populations
This study is looking at how a new rule to lower nicotine in cigarettes could help people, especially those with major depression and women facing economic challenges, by making it easier for them to quit smoking and improve their health.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10870166 on NIH RePORTER |
What this research studies
This research investigates the potential health and economic impacts of a proposed regulation to lower nicotine levels in cigarettes to non-addictive amounts. By focusing on vulnerable populations, such as individuals with major depression and socioeconomically disadvantaged women, the study aims to understand how this policy could affect smoking behaviors and health outcomes. Using simulation modeling, the research will evaluate both the health benefits and economic implications of this policy, providing insights into its long-term effects on these groups. The findings could inform public health strategies and regulatory decisions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with major depression and socioeconomically disadvantaged women of reproductive age who smoke.
Not a fit: Patients who do not smoke or are not part of the identified vulnerable populations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to significant reductions in smoking-related health issues and healthcare costs for vulnerable populations.
How similar studies have performed: Previous clinical trials have shown that reduced nicotine cigarettes can decrease smoking rates among vulnerable populations, indicating potential for success in this approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Tam, Jamie Pearl — Yale University
- Study coordinator: Tam, Jamie Pearl
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.